Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Carmen Bozic Sells 2,280 Shares of Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Carmen Bozic sold 2,280 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total value of $1,075,521.60. Following the transaction, the chief marketing officer now directly owns 30,099 shares in the company, valued at approximately $14,198,300.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Carmen Bozic also recently made the following trade(s):

• On Wednesday, June 12th, Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $478.00, for a total value of $1,089,840.00.
• On Wednesday, May 29th, Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $445.56, for a total value of $1,015,876.80.

Vertex Pharmaceuticals Stock Down 0.8 %

Shares of Vertex Pharmaceuticals stock opened at $468.72 on Friday. The business’s fifty day moving average price is $444.89 and its two-hundred day moving average price is $426.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The company has a market capitalization of $120.95 billion, a P/E ratio of 30.42, a PEG ratio of 2.43 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1-year low of $335.82 and a 1-year high of $486.42.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.58 billion. During the same quarter in the previous year, the business earned $2.67 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current year.

Wall Street Analyst Weigh In

VRTX has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $462.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 7th. Piper Sandler lifted their target price on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. BMO Capital Markets lifted their target price on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, May 31st. Canaccord Genuity Group reiterated a “sell” rating and issued a $371.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. Finally, Guggenheim raised their price target on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $448.61.

Institutional Trading of Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. NBW Capital LLC raised its stake in shares of Vertex Pharmaceuticals by 5.2% in the 1st quarter. NBW Capital LLC now owns 20,443 shares of the pharmaceutical company’s stock worth $8,545,000 after buying an additional 1,011 shares in the last quarter. Jackson Wealth Management LLC raised its stake in shares of Vertex Pharmaceuticals by 1.3% in the 1st quarter. Jackson Wealth Management LLC now owns 3,555 shares of the pharmaceutical company’s stock worth $1,486,000 after buying an additional 46 shares in the last quarter. Railway Pension Investments Ltd raised its stake in shares of Vertex Pharmaceuticals by 0.9% in the 1st quarter. Railway Pension Investments Ltd now owns 99,700 shares of the pharmaceutical company’s stock worth $41,676,000 after buying an additional 900 shares in the last quarter. Motiv8 Investments LLC raised its stake in shares of Vertex Pharmaceuticals by 24.8% in the 1st quarter. Motiv8 Investments LLC now owns 1,410 shares of the pharmaceutical company’s stock worth $589,000 after buying an additional 280 shares in the last quarter. Finally, Cetera Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 63.2% in the 1st quarter. Cetera Advisors LLC now owns 13,912 shares of the pharmaceutical company’s stock worth $5,815,000 after buying an additional 5,390 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.